The drug discovery portal: A computational platform for identifying drug leads from academia

Current Pharmaceutical Design

Volumn 16, Issue 15, 2010, Pages 1697-1702

  Clark, Rachel L ^a   Johnston, Blair F ^a   Mackay, Simon P ^a   Breslin, Catherine J ^a   Robertson, Murray N ^a   Sutcliffe, Oliver B ^a   Dufton, Mark J ^a   Harvey, Alan L ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Academic drug discovery; Chemical diversity; Natural products; Virtual screening

Indexed keywords

ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; JANUS KINASE 2 INHIBITOR; OPIATE;

ALLOSTERISM; ARTICLE; CYTOTOXICITY; DATA BASE; DRUG IDENTIFICATION; DRUG PROGRAM; DRUG SCREENING; HUMAN; LIBRARY; MOLECULAR DOCKING; PATENT; PHARMACOPHORE; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; SCIENTIFIC LITERATURE; UNITED KINGDOM; UNIVERSITY; VIRTUAL REALITY; CHEMICAL STRUCTURE; DRUG DESIGN; DRUG DEVELOPMENT; EDUCATION; FACTUAL DATABASE; METHODOLOGY; PHARMACEUTICS; RESEARCH;

DATABASES, FACTUAL; DRUG DESIGN; DRUG DISCOVERY; MOLECULAR STRUCTURE; RESEARCH; SCOTLAND; TECHNOLOGY, PHARMACEUTICAL; UNIVERSITIES;

EID: 78049509459     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161210791164018     Document Type: Article

References (33)

1. Kruger DM, Evers A. Comparison of structure- and ligand-based virtual screening protocols considering hit list complementarity and enrichment factors. Chem Med Chem 2009; 5: 148-158.
2. Ghosh S, Nie A, An J, Huang Z. Structure-based virtual screening of chemical libraries for drug discovery. Curr Opin Chem Biol 2006; 10: 194-202.
3. Phatak SS, Stephan CC, Cavasotto CN. High-throughput and in silico screenings in drug discovery. Exp Opin Drug Discov 2009; 4: 947-959.
4. AB. Available at: http://www.biognos.se [accessed January 11, 2010].
5. Irwin JJ, Shoichet BK, Mysinger M, Huang N, Colizzi F, Wassam P, Cao Y. Automated docking screens: a feasibility study. J Med Chem 2009; 52: 5712-5720.
6. BioFocus (a Galapagos Company). Available at: http://www.biofocus.com/ [accessed December 18, 2009].
7. Quantum Pharmaceuticals. Available at: http://q-pharm.com[accessed January 11, 2010].
8. Villar HO, Hansen MR. Design of chemical libraries for screening. Exp Opin Drug Discov 2009; 4: 1215-1220.
9. Frearson JA, Collie IT. HTS and hit finding in academia - from chemical genomics to drug discovery. Drug Discov Today 2009; 14(23-24): 1150-1158.
10. Archer JR. History, evolution, and trends in compound management for high throughput screening. Assay Drug Dev Technol 2004; 2: 675-681.
11. 2). Available at: https://pd2.lilly.com/ [accessed December 18, 2009].
12. Hope J. Biobazaar the open source revolution and biotechnology. Boston: Harvard College 2008.
13. Chimiotheque Nationale. Available at: http://chimiotheque-nationale.enscm.fr/ [accessed November 16, 2009].
14. Maybridge HitFinder (version 7) database. Maybridge, Trevillet, Tintagel, Cornwall, UK 2007.
15. BioSPECS natural product database. Netherlands 2007.
16. Interbioscreen databases. Moscow, Russia: Interbioscreen Ltd., 2007.
17. ChemDiv Small Molecule Compound Collection. San Diego, CA, USA: ChemDiv Inc. 2008.
18. Catalyst/World Drug Index Derwent database. Cambridge, UK: Accelrys 2005.
19. Hergenrother PJ. Obtaining and screening compound collections: a user's guide and a call to chemists. Curr Opin Chem Biol 2006; 10: 213-218.
20. Davies J, Glick M, Jenkins J. Streamlining lead discovery by aligning in silico and high-throughput screening. Curr Opin Chem Biol 2006; 10: 343-351.
21. Good A, Krystek S, Mason J. High-throughput and virtual screening: core lead discovery technologies move towards integration. Drug Discov Today 2000; 5: S61-S69.
22. Klebe G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 2006; 11: 580-594.
23. McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol 2007; 11: 494-502.
24. Waszkowycz B. Towards improving compound selection in structure-based virtual screening. Drug Discov Today 2008; 13: 219-226.
25. Accelrys; Accelrys: San Diego, 2009.
26. CCDC: Cambridge, UK, 2009.
27. Hibert MF. French/European academic compound library initiative. Drug Discov Today 2009; 14: 723-5.
28. Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol 2007; 83: 293-309.
29. Jacobson KA, Gallo-Rodriguez C, Melman N, Fischer B, Maillard M, van Bergen A, et al. Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J Med Chem 1993; 36: 1333-1342.
30. Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawl using kratom (Mitragynia speciosa korth). Addiction 2008; 103: 1048-1050.
31. Schrödinger, LLC. Portland, OR, 2009.
32. Accelrys: Cambridge, UK, 2009.
33. Pritchard L, Cardle L, Quinn S, Dufton M. Simple intrasequence difference (SID) analysis: an original method to highlight and rank sub-structural interfaces in protein folds. Application to the folds of bovine pancreatic trypsin inhibitor, phospholipase A2, chymotrypsin and carboxypeptidase A. Prot Eng 2003; 16: 87-101.